OGEN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OGEN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Oragenics's Cash Ratio for the quarter that ended in Mar. 2024 was 2.28.
Oragenics has a Cash Ratio of 2.28. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Oragenics's Cash Ratio or its related term are showing as below:
During the past 13 years, Oragenics's highest Cash Ratio was 42.00. The lowest was 1.14. And the median was 7.13.
The historical data trend for Oragenics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Ratio | Get a 7-Day Free Trial | 9.87 | 13.14 | 18.87 | 7.16 | 1.94 |
Oragenics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Ratio | Get a 7-Day Free Trial | 5.14 | 5.67 | 4.11 | 1.94 | 2.28 |
For the Biotechnology subindustry, Oragenics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oragenics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Oragenics's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Oragenics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Ratio (A: Dec. 2023 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 3.484 | / | 1.798 | |
= | 1.94 |
Oragenics's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:
Cash Ratio (Q: Mar. 2024 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 2.072 | / | 0.909 | |
= | 2.28 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics (AMEX:OGEN) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Oragenics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Fred Telling | director | 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119 |
John P Gandolfo | director | 62 TERRACE ROAD, WAYNE NJ 07470 |
Cassidy Bruce A. Sr. | director | C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203 |
Janet Huffman | officer: CFO, Secretary and Treasurer | 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232 |
Robert C Koski | director, 10 percent owner | 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243 |
Michael O'keefe Sullivan | officer: CFO, Secretary and Treasurer | 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607 |
Joseph Hernandez | 10 percent owner | C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
Kimberly M Murphy | director | 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602 |
Koski Family Lp | 10 percent owner | 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243 |
Randal J Kirk | 10 percent owner | 1881 GROVE AVENUE, RADFORD VA 24141 |
Alan Joslyn | director, officer: CEO and President | 39 OLD RIDGEBURY ROAD, DANBURY CT 06810 |
Charles L Pope | director | 4902 EISENHOWER BOULEVARD, TAMPA FL 33634 |
Christine L Koski | director, 10 percent owner | 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243 |
Beverly Koski | 10 percent owner | |
Thomas L Koski | 10 percent owner |
From GuruFocus
By PRNewswire PRNewswire • 01-04-2022
By PRNewswire PRNewswire • 10-06-2020
By GuruFocus Research GuruFocus Editor • 01-14-2022
By PRNewswire PRNewswire • 10-04-2018
By PRNewswire PRNewswire • 05-19-2020
By PRNewswire PRNewswire • 08-20-2020
By Marketwired Marketwired • 06-20-2018
By PRNewswire PRNewswire • 07-10-2020
By PRNewswire PRNewswire • 07-22-2020
By PRNewswire PRNewswire • 12-20-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.